Clinical and pharmacological group: & nbsp

Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists

Included in the formulation
  • Genotropin®
    lyophilizate PC 
  • Gentropine
    lyophilizate PC 
    Europharm (UK) Co., Ltd.     United Kingdom
  • Dinatrop®
    lyophilizate PC 
  • Novo Nordisk A / S     Denmark
  • Novo Nordisk A / S     Denmark
  • Omnitrop®
    solution PC 
    Sandoz GmbH     Austria
  • Rastan®
    solution PC 
  • Saizen®
    lyophilizate PC 
    Merck Serono SpA     Italy
  • Humatrop®
    lyophilizate PC 
    Lilly France     France
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    7 nosologies

    ONLS

    АТХ:

    H.01.A.C   Somatropin and its analogues

    H.01.A.C.01   Somatropin

    Pharmacodynamics:

    The analog of human growth hormone, obtained by genetic engineering, containing exactly the same amino acid sequence as in natural somatotropin, stimulates the secretion of insulin-like growth factors-somatomedins. The insulin-like growth factor (IGFR-1) formed in the liver affects the receptors of peripheral tissues, which leads to activation of mitogen-active protein kinase and some types of intermediate metabolism.As a result of the anabolic action of the drug, protein biosynthesis, the growth of muscle and bone tissue, urinary output of nitrogenous products decreases, calcium, phosphorus and sodium are retained.

    Pharmacokinetics:

    After subcutaneous administration, the maximum concentration in the blood plasma is reached after 3-6 hours. Metabolism in the liver.

    Half-life is 2-3 hours. Elimination with feces.
    Indications:

    It is used for growth disorders in children due to insufficient endogenous growth hormone, chronic renal failure, manifested by growth retardation, osteoporosis, Turner syndrome, immunodeficiency states with weight loss.

    III.D80-D89.D84.9   Immunodeficiency, unspecified

    IV.E20-E35.E34.3   Low-growth [dwarfism], not elsewhere classified

    XVII.Q90-Q99.Q96   Turner syndrome

    XVIII.R50-R69.R62   The absence of the expected normal physiological development

    Contraindications:

    Malignant neoplasms, individual intolerance.

    Carefully:

    Diabetes mellitus, deficiency of thyroid function.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Subcutaneously or intramuscularly 1 time / day at 0.07-0.1 IU / kg. In some cases, the dose may be raised to 0.14-0.2 IU / kg.

    The highest daily dose: 0.14 IU / kg.

    The highest single dose: 0.2 IU / kg.

    Side effects:

    Central and peripheral nervous system: headache, paresthesia, rarely - carpal tunnel syndrome in adults, benign intracranial hypertension.

    The system of hematopoiesis: rarely - leukemia.

    The musculoskeletal system: acromegaly, arthralgia, myalgia, rigidity of the limbs, rarely epiphysiolysis with hip joint lesion.

    Endocrine system: diabetes mellitus II type.

    Allergic reactions.

    Overdose:

    Hypoglycemia, which turns into hyperglycemia.

    Treatment is symptomatic.

    Interaction:

    Simultaneous use with glucocorticoids reduces the therapeutic effect of somatropin.

    The use of anabolic steroids enhances the effect of somatropin.

    Special instructions:

    It is used before the period of bone growth.

    Monitoring the content of blood plasma glucose, thyroid hormones.

    To avoid the development of lipotrophy, it is recommended to alternate injection sites.

    Instructions
    Up